Given their specific roles in tumor development and progression, as well as their unique structural characteristics, HDAC4 and HDAC6 have been identified as promising targets for the development of multi-target HDAC/ROCK inhibitors [30,31]. The gene discussed is HDAC6; the disease is neoplasm.